FATE
Price
$1.69
Change
+$0.03 (+1.81%)
Updated
Dec 20, 04:59 PM (EDT)
72 days until earnings call
IDYA
Price
$25.61
Change
+$0.82 (+3.31%)
Updated
Dec 20, 04:59 PM (EDT)
101 days until earnings call
Ad is loading...

FATE vs IDYA

Header iconFATE vs IDYA Comparison
Open Charts FATE vs IDYABanner chart's image
Fate Therapeutics
Price$1.69
Change+$0.03 (+1.81%)
Volume$97.27K
CapitalizationN/A
IDEAYA Biosciences
Price$25.61
Change+$0.82 (+3.31%)
Volume$32.17K
CapitalizationN/A
FATE vs IDYA Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. IDYA commentary
Dec 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and IDYA is a Hold.

COMPARISON
Comparison
Dec 21, 2024
Stock price -- (FATE: $1.69 vs. IDYA: $25.61)
Brand notoriety: FATE and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 307% vs. IDYA: 210%
Market capitalization -- FATE: $192.48M vs. IDYA: $2.21B
FATE [@Biotechnology] is valued at $192.48M. IDYA’s [@Biotechnology] market capitalization is $2.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, both FATE and IDYA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 3 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).

  • FATE’s TA Score: 3 bullish, 6 bearish.
  • IDYA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -7.65% price change this week, while IDYA (@Biotechnology) price change was +1.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

FATE is expected to report earnings on Mar 03, 2025.

IDYA is expected to report earnings on Apr 01, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.21B) has a higher market cap than FATE($192M). IDYA YTD gains are higher at: -28.021 vs. FATE (-54.813). FATE has higher annual earnings (EBITDA): -177.57M vs. IDYA (-220.54M). IDYA has more cash in the bank: 920M vs. FATE (297M). IDYA has less debt than FATE: IDYA (18.8M) vs FATE (99M). FATE has higher revenues than IDYA: FATE (13.4M) vs IDYA (3.92M).
FATEIDYAFATE / IDYA
Capitalization192M2.21B9%
EBITDA-177.57M-220.54M81%
Gain YTD-54.813-28.021196%
P/E RatioN/AN/A-
Revenue13.4M3.92M342%
Total Cash297M920M32%
Total Debt99M18.8M527%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATEIDYA
RSI
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
66%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 13 days ago
86%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEGBX128.511.12
+0.88%
MFS Growth B
FTEIX11.380.01
+0.09%
Fidelity Advisor Total Intl Equity I
PMIEX24.28N/A
N/A
Federated Hermes International Equity A
FARLX13.12N/A
N/A
FS Chiron Real Development A
TEBIX15.60-0.52
-3.25%
Franklin Mutual Beacon A

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+1.81%
ALLO - FATE
58%
Loosely correlated
+1.63%
RCKT - FATE
51%
Loosely correlated
+2.03%
PIRS - FATE
51%
Loosely correlated
N/A
CRBU - FATE
51%
Loosely correlated
-0.83%
CCCC - FATE
50%
Loosely correlated
+2.60%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+3.31%
GRI - IDYA
54%
Loosely correlated
-3.90%
PLRX - IDYA
47%
Loosely correlated
-0.60%
PGEN - IDYA
47%
Loosely correlated
+5.07%
INAB - IDYA
47%
Loosely correlated
+3.49%
RCKT - IDYA
46%
Loosely correlated
+2.03%
More